Stiolto Respimat (olodaterol/tiotropium FDC) / Boehringer Ingelheim - LARVOL DELTA

Airway Response to Dual Bronchodilation and Its Association with Inflammatory Markers in Treatment-Naïve Chronic Obstructive Pulmonary Disease: A Quantitative Computed Tomography Study. (PubMed, Life (Basel)) - "Lung function and chest CT were assessed at baseline and after 12 weeks of tiotropium/olodaterol (n = 34)... Initial dual bronchodilator therapy improved lung function and CT-derived airway measurements. In this cohort, no statistically significant association was detected between blood eosinophil count and airway response, whereas higher hs-CRP was associated with a smaller Ai/BSA increase."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • CRP

Editorial for "Effects of Single and Multiple Dose Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease on Alveolar Gas Exchange Measured by Hyperpolarized 129Xe MRI". (PubMed, J Magn Reson Imaging) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effects of Single and Multiple Dose Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease on Alveolar Gas Exchange Measured by Hyperpolarized 129Xe MRI. (PubMed, J Magn Reson Imaging) - "Single-dose TIO/OLO increased 129Xe in RBC-Gas. Multiple-dose treatment increased M-Gas and further increased RBC-Gas compared to single-dose treatment."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effects of dual bronchodilation on health-related quality of life and exercise physiology in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease: a real-world study (ERS 2026) - " Thirty-two newly diagnosed moderate-to-severe COPD patients were examined at baseline and after 12 weeks of treatment with tiotropium/olodaterol... In a real-world setting, dual bronchodilation improved physical functioning and exercise physiology in treatment-naïve COPD; the greatest gains in breathing reserve were observed in patients with greater baseline ventilatory limitation, independent of beta-blocker use. These findings support early dual bronchodilation alongside appropriate management of comorbidities."

Clinical • HEOR • Real-world • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparative efficacy of once-daily LAMA/LABA combinations versus tiotropium on constant-work-rate cycle endurance in COPD: a randomized crossover pilot study (COMPETE) (ERS 2026) - "Four treatments were administered in a randomized order (28 days each, 7-day washout): tiotropium/olodaterol, umeclidinium/vilanterol, indacaterol/glycopyrronium, and tiotropium. We demonstrate that head-to-head CWRCE method can be a useful test for assessing the effect of individual medications and their combinations on exercise tolerance. The high interpatient variability highlights the potential for personalized bronchodilator selection based on CPET, justifying further study in larger cohorts."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Effect of Tiotropium/Olodaterol soft mist inhalers on dynamic changes in lung mechanics of patients with COPD receiving mechanical ventilation (ERS 2026) - "Tiotropium/Olodaterol SMI effectively improves mechanics and oxygenation in ventilated COPD patients, likely by mitigating hyperinflation. This regimen offers substantial clinical value, particularly for the elderly (>65 years), by optimizing mechanics without increasing dosing frequency, thereby reducing costs and preserving resources."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Renal Cell Carcinoma • Respiratory Diseases

Respiratory Mechanics After Inline Delivery of Tiotropium/Olodaterol During Mechanical Ventilation. (PubMed, Respir Care) - "Inline delivery of tiotropium/olodaterol during mechanical ventilation was feasible and was associated with changes in respiratory mechanics in COPD subjects. Given the observational design and absence of a control group, these findings should be interpreted as physiologic observations rather than evidence of treatment efficacy."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

TQC3302-I-01: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | N=57 ➔ 33 | Trial completion date: Dec 2026 ➔ Aug 2026 | Recruiting ➔ Terminated; This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation Spray.

Enrollment change • Trial completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study. (PubMed, Ther Adv Respir Dis) - P | "COPD affects RV function and troponin-I regardless of concomitant CVDs. Initiation of dual bronchodilation is associated with beneficial effects on RV strain and troponin-I in patients with COPD. Because of the small sample size, these findings should be interpreted cautiously and confirmed in larger studies."

Biomarker • Journal • Observational data • Real-world evidence • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD. (PubMed, ERJ Open Res) - "These results underscore the importance of continued dual bronchodilator therapy to achieve cardiovascular improvements. The nonsignificant rise in MSNA after a single dose suggests minimal immediate effect on sympathetic activity; further studies are necessary to evaluate long-term autonomic outcomes."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. (PubMed, J Thorac Dis) - "This study evaluated post-marketing safety signals for four dual bronchodilators (formoterol/glycopyrronium, indacaterol/glycopyrronium, vilanterol/umeclidinium, and olodaterol/tiotropium). Olodaterol/tiotropium showed signals for ileus, retinal vein occlusion, cataract, and hip fracture, and exhibited the longest latency period among the other three bronchodilators. This pharmacovigilance study identified significant safety signals associated with four bronchodilators, highlighting both common and drug-specific disproportionality signals and thereby providing essential evidence to support drug monitoring in clinical practice."

Adverse events • FDA event • Journal • Real-world evidence • Cardiovascular • Cataract • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Immunology • Musculoskeletal Diseases • Myocardial Infarction • Ophthalmology • Orthopedics • Pulmonary Disease • Respiratory Diseases • Retinal Vein Occlusion

Adherence to LAMA/LABA therapies in middle-aged patients with chronic obstructive pulmonary disease: A group-based trajectory analysis. (PubMed, Respir Investig) - "Middle-aged patients with COPD initiating LAMA/LABA therapy exhibited distinct adherence trajectories. Understanding these patterns may help inform more targeted approaches to support adherence and improve patient outcomes."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Phase-resolved functional lung MRI detects single-dose and sustained bronchodilator responses in COPD in a randomized crossover trial. (PubMed, Eur Radiol) - "Question Can phase-resolved functional lung (PREFUL) MRI sensitively capture immediate single-dose and sustain multi-dose effects of tiotropium/olodaterol on ventilation-perfusion and vascular function in COPD patients? Findings Tiotropium/olodaterol improved PREFUL MRI-derived ventilation, perfusion, and V/Q matching parameters after a single dose, with sustained pulmonary vascular improvements after repeated dosing. Clinical relevance PREFUL MRI detected immediate and sustained functional improvements after tiotropium/olodaterol and showed significant correlations with cardiopulmonary tests and hyperpolarized ¹²⁹Xe MRI, supporting its role as a sensitive, radiation-free tool for monitoring COPD treatment response."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

COMPETE: Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD (clinicaltrials.gov) - P=N/A | N=100 | Suspended | Sponsor: Medical University of Bialystok

New trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Simultaneous quantification and aerodynamic particle size distribution analysis of tiotropium bromide and olodaterol in nebulized aerosol using UHPLC-MS/MS. (PubMed, J Pharm Biomed Anal) - "Application of this method to the evaluation of theoretical delivered doses in animal safety assessment tests showed that the doses were 4.7-8.6 times the rat equivalent dose, meeting the design requirements for toxicological studies. This method provides a robust framework for quality control, generic drug consistency evaluation, and preclinical toxicology of TTP/ODT nebulized aerosols, supporting the development of FDC inhaled therapies for chronic obstructive pulmonary disease (COPD)."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE] (clinicaltrials.gov) - P=N/A | N=44 | Completed | Sponsor: Yonsei University | Not yet recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Real-World Impact of Initial Dual Bronchodilation on Exercise Physiological Response and Health-Related Quality of Life in Newly Diagnosed, Treatment-Naïve Chronic Obstructive Pulmonary Disease. (PubMed, Medicina (Kaunas)) - "Following baseline assessment, COPD patients received tiotropium/olodaterol as part of routine practice...Dual bronchodilation improved exercise responses and perceived physical functioning. Beta-blocker use was not associated with changes in breathing reserve, supporting the use of cardioselective agents when indicated."

HEOR • Journal • Real-world evidence • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Dynamic Chest Radiography Assessment of Tiotropium/Olodaterol Therapy in Chronic Obstructive Pulmonary Disease: Findings From the Embody Study (ATS 2026) - No abstract available

Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease. (PubMed, JAMA Intern Med) - "This cohort study found that umeclidinium-vilanterol was associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol. Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy."

HEOR • Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Nephrology • Pneumonia • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Hanmi Pharm to sell 3 Boehringer COPD inhalers in Korea, including Spiriva and Vahelva (Korea Biomedical Review) - "Hanmi said domestic distribution and promotion will begin shortly."

Commercial • Chronic Obstructive Pulmonary Disease

TUSSIVE SYNCOPE IN A PATIENT WITH INFLUENZA B AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (CHEST 2025) - "After testing positive for Influenza B, he was prescribed oseltamivir. He was advised to continue his COPD medications, including triple therapy (fluticasone, umeclidinium, vilanterol) and ipratropium/albuterol inhalers...He returned to his primary care provider 3 days later, who started him on amoxicillin-clavulanate, benzonatate, and prednisone...He was treated with budesonide and albuterol nebulizers, tiotropium/olodaterol inhaler, IV methylprednisolone, diphenhydramine plus hydrocodone, and azithromycin... Patients with influenza and comorbidities such as COPD and coronary artery disease should be assessed for signs of syncope, particularly in those with prolonged and intense coughing episodes. Additionally, patient education and close monitoring are crucial to reduce the risk of fall-related injuries."

Clinical • Cardiovascular • Chronic Cough • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension • Hypotension • Immunology • Infectious Disease • Influenza • Musculoskeletal Diseases • Obstructive Sleep Apnea • Orthopedics • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL. (PubMed, Int J Chron Obstruct Pulmon Dis) - "TIO/OLO initiators incurred lower pharmacy costs related to COPD and/or pneumonia than FF/UMEC/VI initiators. These results support treatment recommendations of reserving inhaled corticosteroids for frequent exacerbators and patients with elevated eosinophil counts."

Clinical • Clinical data • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease[ACHIEVE] (ERS 2025) - P=N/A | "Tiotropium/olodaterol therapy offers potential benefits in improving exercise capacity in patients with COPD, particularly in those with lower baseline exercise capacity and pulmonary hyperinflation (NCT04994574)."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

The effect of tiotropium/olodaterol on lung, right ventricular function and serum troponin I levels in patients with moderate chronic obstructive pulmonary disease (ERS 2025) - "COPD treatment with TIO/OLO not only improves lung function but also might have a positive effect on right ventricular strain and reduce serum troponin I levels. Due to cardiovascular involvement in COPD early use of dual bronchodilation is very important."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases